Sulfaphenazole
Sulfaphenazole structure
|
Common Name | Sulfaphenazole | ||
|---|---|---|---|---|
| CAS Number | 526-08-9 | Molecular Weight | 314.362 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 541.9±56.0 °C at 760 mmHg | |
| Molecular Formula | C15H14N4O2S | Melting Point | 179-183ºC | |
| MSDS | Chinese USA | Flash Point | 281.5±31.8 °C | |
Use of SulfaphenazoleSulfaphenazole is a specific inhibitor of CYP2C9 which blocks atherogenic and pro-inflammatory effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Acts as an antibacterial and antimicrobial. |
| Name | sulfaphenazole |
|---|---|
| Synonym | More Synonyms |
| Description | Sulfaphenazole is a specific inhibitor of CYP2C9 which blocks atherogenic and pro-inflammatory effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Acts as an antibacterial and antimicrobial. |
|---|---|
| Related Catalog |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 541.9±56.0 °C at 760 mmHg |
| Melting Point | 179-183ºC |
| Molecular Formula | C15H14N4O2S |
| Molecular Weight | 314.362 |
| Flash Point | 281.5±31.8 °C |
| Exact Mass | 314.083740 |
| PSA | 98.39000 |
| LogP | 1.52 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.684 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
|
~%
Sulfaphenazole CAS#:526-08-9 |
| Literature: CIBA Patent: US2858309 , 1957 ; |
![Carbanilic acid, p-[(1-phenylpyrazol-5-yl)sulfamoyl]-, ethyl ester structure](https://image.chemsrc.com/caspic/442/93880-94-5.png)
| Precursor 1 | |
|---|---|
| DownStream 0 | |
| HS Code | 2935009090 |
|---|---|
| Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Chem. Res. Toxicol. 23 , 171-83, (2010) Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental... |
|
|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ... |
|
|
Convenient QSAR model for predicting the complexation of structurally diverse compounds with β-cyclodextrins
Bioorg. Med. Chem. 17 , 896-904, (2009) This paper reports a QSAR study for predicting the complexation of a large and heterogeneous variety of substances (233 organic compounds) with beta-cyclodextrins (beta-CDs). Several different theoret... |
| Benzenesulfonamide, 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)- |
| MFCD00057226 |
| EINECS 208-384-3 |
| 4-amino-N-(2-phenylpyrazol-3-yl)benzenesulfonamide |
| 4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide |
| Sulfaphenazole |